| Nov 20 |
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average
|
| Nov 20 |
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors
|
| Nov 19 |
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now
|
| Nov 19 |
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average
|
| Nov 18 |
Arcutis Biotherapeutics: What Lies Ahead
|
| Nov 15 |
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
|
| Nov 13 |
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
|
| Nov 11 |
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
|
| Nov 8 |
Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 7 |
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript
|
